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Abstract: The present study investigated the effect of methyleugenol, a food flavoring and fragrance agent, on the livers
of laboratory rats. Doses of 10 and 30 mg/kg/day of methyleugenol (in 0.5% methylcellulose) were administered
intragastrically (IG) to 2 dose groups for 10 days alongside a control group (n = 10 for each group). Gains in body weight
were not statistically significant for either dose. Lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) activities
decreased (P < 0.05) for both dose groups, but AST (aspartate aminotransferase) activity decreased significantly (P <
0.05) only in the 30 mg/kg/day methyleugenol dose group. Alanine aminotransferase (ALT) activity did not change
significantly in either group. The total amount of glucose remained unchanged, but glycogen in the liver decreased
significantly (P < 0.05) in the 30 mg/kg/day methyleugenol dose group. There was also an increase of swelling in the
smooth endoplasmic reticulum sacs (sER), electron dense accumulations in the sER, cytoplasmic vacuolization, a slight
increase of mitochondria and lysosomes, and invaginations in the nucleus membranes of hepatocytes. Extensions in bile
canaliculi and increasing microvilli of bile canaliculi in the liver were also observed. These findings indicate the
ultrastructural toxic effect of methyleugenol on rat livers in 10 and 30 mg/kg/day doses. Therefore, we may speculate that
the toxic effect of methyleugenol needs to be examined in detail.
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Sıçan karaciğerinde metileugenol etkisi ile meydana gelen ince yapı
değişiklikleri ve bazı biyokimyasal parametrelerin değerlendirilmesi
Özet: Mevcut çalışmada gıdalar için lezzet ve koku ajanı olan methileugenolün sıçanların karaciğer dokusu üzerine
etkileri araştırılmıştır. Metileugenolün 10 and 30 mg/kg/gün dozları (% 0,5 metilselüloz içinde) kontrol grubunun yanı
sıra iki doz grubuna intragastrik yolla on gün süreyle verilmiştir (her grup için, n = 10). Vücut ağırlığındaki değişim doz
gruplarında istatistiksel olarak anlamlı değildir. Laktat dehidrogenaz (LDH) and alkalin fosfataz (ALP) aktiviteleri her
iki doz grubunda (P < 0,05) fakat AST (aspartat aminotransferaz) aktivitesi sadece 30 mg/kg/gün methyleugenol
grubunda anlamlı şekilde (P < 0,05) azalmıştır. Alanin aminotransferaz (ALT) aktivitesi her iki doz grubunda da anlamlı
değişiklik göstermemiştir. Karaciğerde total glukoz miktarı değişmeden kalırken, glikojen miktarı 30 mg/kg/gün
metileugenol grubunda anlamlı şekilde (P < 0,05) azalmıştır. Aynı zamanda, hepatositlerde, düz yüzlü endoplazmik
retikulum keselerinde şişme, artış ve elektron yoğun birikimler, sitoplazmik vakuolizasyon, mitokondri ve lizozom
sayısında hafif bir artış, nukleus zarında invaginasyon meydana gelmiştir. Ayrıca safra kanalikülilerinde genişleme ve
kanaliküllerde microvillus artışı gözlenmiştir. Bu bulgular, metileugenolün 10 and 30 mg/kg/gün dozlarında sıçan
karaciğeri üzerine ultrastrüktürel düzeyde toksik etkisine işaret etmektedir. Bu nedenle metileugenolün toksik etkilerinin
daha ayrıntılı şekilde araştırılması gerektiğini düşünmekteyiz.
Anahtar sözcükler: Metileugenol, karaciğer, ultrastruktür, ALT, AST, LDH, ASP, glukoz, glikojen, sıçan
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Introduction
Methyleugenol is an analogue of the phenolic
compound eugenol, and it is a natural constituent of
the essential oils of a number of plants widely used in
food as flavoring agents (1,2). This alkenylbenzene
compound is also used to fragrance cosmetic products
such as soaps, shampoos, lotions, and perfumes (3).
The reported LD50 values of methyleugenol were 850
mg/kg for rats and 540 mg/kg for mice (4). Many
biological effects of methyleugenol have previously
been reported. Methyleugenol has antibacterial
properties (5) and relaxant and antispasmodic actions
on the ileum (6). It has been shown to have a
depressive effect on the central nervous system with
anesthetic, hypothermic, myorelaxant, and
anticonvulsant properties (7). Furthermore,
methyleugenol has been reported to cause cytotoxicity
when measuring lactate dehydrogenase (LDH) release
and genotoxicity by using the unscheduled DNA
synthesis (UDS) assay in cultured primary
hepatocytes of rodents, similar to that caused by
safrole or other alkenylbenzene compounds such as
eugenol and isoeugenol (3,8). Mutagenicity studies
have found that methyleugenol has mutagenic effects
in the yeast assay (9,10). Several toxic effects have also
been noted, such as hepatocellular injury, altered
hepatic function, adrenal hypertrophy at doses of 100
mg/kg or more, reduction of serum total protein and
albumin, increases in serum gastrin and gastric pH at
doses of 300 or 1000 mg/kg, and increases in serum
alanine aminotransferase and sorbitol dehydrogenase
activities and bile acid concentration. The noobserved-effect level (NOEL) of methyleugenol for
rats and mice was estimated at 10 mg/kg (11).
Unfortunately, there are currently no data regarding
the toxicity of methyleugenol that include an
ultrastructural evaluation. Therefore, we aimed to
determine the toxic effect of methyleugenol at 10 and
30 mg/kg/day doses with this ultrastructural and
biochemical study.
Materials and methods
Chemicals and dose preparation
Methyleugenol (CAS No. 93-15-2; 99% pure) and
methylcellulose (CAS No. 9004-67-5) were purchased
from the Merck Chemical Company (Hohenbrunn,
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Germany) and the Sigma-Aldrich Chemical
Company (Steinheim, Germany), respectively.
Methyleugenol doses were prepared by diluting the
chemical with a 0.5% aqueous methylcellulose
suspension, and 2 doses (10 mg/kg/day and 30
mg/kg/day) were administered intragastrically. All
other chemicals and reagents used were of analytical
grade.
Animals and treatments
Thirty Wistar albino male rats (3 months old,
weighing 235 ± 35 g) were obtained from the
Department of Experimental Animals of Trakya
University, Edirne, Turkey. They were fed standard
pellets (including 21% pure protein) and had free
access to the water under optimum laboratory
conditions (temperature: 21 °C; humidity: 40%-60%;
light/dark period: 12 h/12 h; optimum air
conditioning system).
Animals were randomly divided into 2
methyleugenol-treated groups and a control group of
10 rats each (n = 10). The first methyleugenol-treated
group was given 10 milligrams per kilogram of body
weight day of methyleugenol (in 0.5%
methylcellulose) and the second group was given 30
mg/kg/day, both by gavage for 10 days. The control
group received 0.5% methylcellulose on the same
dosing schedule simultaneously. The body weight of
the animals was measured and recorded at the
beginning and end of the experiment.
Biochemical assay
After 10 days, the animals were anesthetized with
5-10 mg/kg Rompun (2%) (xylazine hydrochloride)
from Bayer (İstanbul, Turkey) and 50-70 mg/kg
Ketasol (10%) from Richter Pharma (Wels, Austria),
and then blood samples were taken from the heart for
an enzyme assay (ALT, AST, LDH, and ASP). Enzyme
activities were measured using an autoanalyzer
(Abbott, Architect C-8000) at Trakya University,
School of Medicine, Central Laboratory, Edirne,
Turkey.
Liver samples were dissected, washed with cold
0.9% saline, and kept frozen at -80 °C until
homogenized. Glucose amounts in the liver tissue
were determined following homogenization by a
glass-glass homogenizer using the o-toluidine method
(12), and glycogen amounts were measured using an
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anthrone reagent (13) by spectrophotometer
(Shimadzu-1240, UV-VIS).

This study was approved by the Local Ethical
Committee of Trakya University’s School of Medicine.
Statistical analysis
All data were tested for normality using the
Kolmogorov-Smirnov test. Normally distributed data
were tested using an ANOVA test and then pair-wise
comparisons were conducted using Bonferroni’s test.
Means are given with standard deviations (mean ±
SD). P < 0.05 was considered statistically significant in
the analyses.
Results

Animal Weight (g)

The animals of each group were killed by
decapitation and then the liver specimens of all
groups were processed for electron microscopic
examination. Liver pieces of 1-2 mm in size were fixed
in 4% glutaraldehyde in 0.1 M phosphate buffer (pH
7.2-7.3), and, after primary fixations, tissues were
washed in 0.1 M phosphate buffer overnight. The
tissues were postfixed with 1% osmium tetroxide in
phosphate buffer for 1 h at 4 °C. The postfixed tissues
were then washed in 0.1 M phosphate buffer and
dehydrated using graded ethyl alcohol and, finally,
treated with propylene oxide. Dehydrated tissues were
processed to make araldite-epon 812 blocks. Ultrathin
sections were obtained by ultramicrotome (RMCMTX Ultramicrotome-USA) and collected on copper
grids for double staining (uranyl acetate and
Reynolds’ lead citrate). Stained sections were
observed under a JEOL JEM 1010 transmission
electron microscope.

Beginning of the experiment

End of the experiment
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Figure 1. The effect of methyleugenol on body weight (arithmetic
mean ± SD; standard deviation is given as an error bar).
Body weight values were not significantly different in
the 10 or 30 mg/kg/day methyleugenol groups (P >
0.05).
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Figure 2. The effect of methyleugenol on LDH, ALP, AST, and
ALT. Enzyme activities were measured in serum by
using an autoanalyzer (Abbott, Architect C-8000).
Decreases in LDH and ALP activities were statistically
significant (P < 0.05) for both dose groups, but AST
activity was statistically significant (P < 0.05) in only the
30 mg/kg/day dose group (arithmetic mean ± SD;
standard deviation is given as an error bar).

methyleugenol groups. ALT activity did not change
significantly for either experimental group in
comparison to the control group.

Body weight values were not significantly different
in the 10 mg/kg/day and 30 mg/kg/day methyleugenol
groups compared to the body weight values of the
control group. Body weight values are summarized in
Figure 1.

The total amounts of glucose and glycogen are
shown in Figure 3. Decreases in glucose were
statistically insignificant for both experimental
groups, while the amount of glycogen decreased
significantly (P < 0.05) in the 30 mg/kg/day dose
group compared to the control group.

Enzyme activities (LDH, ALP, AST, and ALT), as
measured by an autoanalyzer, are summarized in
Figure 2. It was observed that AST activity decreased
significantly (P < 0.05) only in the 30 mg/kg/day dose
group. LDH and ALP activities decreased (P < 0.05) in
both the 10 mg/kg/day and 30 mg/kg/day

In the electron microscopic observations, the livers
of the control group rats were visually normal (Figure
4a). In the 10 mg/kg/day methyleugenol-treated
group, we observed an accumulation of electron dense
particles in the sER sacs and invaginations in the
nucleus membranes (Figure 4b). In addition,
441
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Figure 3. The effect of methyleugenol on the total amount of
glucose and glycogen in the liver. Glucose amounts in
the liver tissue were determined by using the o-toluidine
method (12) and glycogen amounts were measured
using an anthrone reagent (13) by spectrophotometer
(Shimadzu-1240, UV-VIS). The amount of glycogen was
significantly decreased (P < 0.05) in only the 30
mg/kg/day dose group (arithmetic mean ± SD; standard
deviation is given as an error bar).

cytoplasmic vacuolization, swelling of the sER sacs,
and a slight increase in the number of mitochondria
were observed in the hepatocytes (Figures 4c and 4d).
In the 30 mg/kg/day methyleugenol-treated group,
extensions in bile canaliculi and an increase of
microvilli of bile canaliculi (Figure 5a), cytoplasmic
vacuolization, swelling of sER sacs, a slight increase
in the number of mitochondria (Figure 5b), a decrease
in glycogen levels (Figure 5c), and an increase of
lysosomes (Figure 5d) were observed in the
hepatocytes.
Discussion
Methyleugenol is widely used in food as a flavoring
agent (1). However, previous research has been
limited to light microscopy and some enzyme
activities for an understanding of methyleugenol
toxicity. Accordingly, in the present study, we
demonstrated dose dependent (10 mg/kg/day and 30

Figure 4. Ultrastructural changes in hepatocytes. a) Control liver. N: nucleus, m: mitochondria, ger: granular endoplasmic reticulum, gl:
glycogen. b) 10 mg/kg methyleugenol. ac: accumulation of electron dense particles, invagination of nucleus membrane. c) and
d) m: increasing of mitochondria, v: vacuolization. Sections were stained with uranyl acetate and Reynolds’ lead citrate.
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Figure 5. Ultrastructural changes in the 30 mg/kg/day methyleugenol-treated group. a), b), and c) m: increasing of mitochondria, bc:
extensions of bile canaliculi, v: vacuolization, N: nucleus. d) *: decrease of cytoplasm, L: increase of lysosomes. Sections were
stained with uranyl acetate and Reynolds’ lead citrate.

mg/kg/day)
methyleugenol
toxicity
ultrastructural changes in the liver.

with

Changes in body weight were not statistically
significant for either dose of methyleugenol (10 and
30 mg/kg/day) compared to the control group. In a
91-day dietary study of methyleugenol (daily intake:
18 mg/kg), body weight was not significantly changed
(14). In a 90-day gavage study using methyleugenol
on mice and rats, the final body weight gains of male
rats receiving 300 and 1000 mg/kg/day and for female
rats receiving all doses were significantly less than the
control group (15). Body weight gains of male and
female mice given 300 mg/kg/day were also
significantly less than in the control group (15). In our
study, the lack of significant weight changes may be
explained by the short treatment period and the use of
lower doses than other studies.

In a study by Abdo et al., an increase in the ALT
serum and a decrease in ALP activity were observed
in connection to 100, 300, and 1000 mg/kg doses, and
increased sorbitol dehydrogenase activities and bile
acid concentrations were observed with 300 and 1000
mg/kg doses of methyleugenol (11). This suggests
hepatocellular injury, cholestasis, or altered function
in rats. They did not observe any changes in these
enzyme activities with 10 or 30 mg/kg methyleugenol
doses. Similarly, we did not find any significantly
changes in ALT activity with 10 or 30 mg/kg/day
doses of methyleugenol in the present study. However,
we did observe significantly decreased AST activity in
the 30 mg/kg/day dose group. We also found
decreases in LDH and ALP activities for both dosage
groups. These alterations of liver enzymes may
indicate ultrastructural liver injury.
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It has been reported that methyleugenol is
metabolized by the cytochrome P450 system in the
liver (16) and that this metabolism involves Odemethylation, side-chain hydrolysis, and epoxide
diol formation (17). 1'-hydroxymethyleugenol and
epoxide diol are the main metabolites of this reaction
and are responsible for the toxic effect of this chemical
(11). We determined slightly increased numbers of
mitochondria and decreased amounts of glycogen in
hepatocytes by electron microscope, as well as
decreased amounts of glycogen with the 30 mg/kg/day
dose of methyleugenol. There was no significant
change in glucose levels for either dose as measured
by spectrophotometer. These findings may be a sign
of the metabolizing processes that need energy, and
increased energy requirements might be provided by
the main energy sources in hepatocytes.
In a 91 day methyleugenol study, normal values
were found in a hematological examination, as well as
normal morphology for 27 major organs using a
histopathological evaluation (14). Previous research
has found Kupffer cell pigmentation, bile duct
hyperplasia of the liver, and atrophy and chronic
inflammation of the mucosa of the glandular stomach
with doses of 100, 300, and 1000 mg/kg
methyleugenol (11). However, no degenerative
changes were found at doses of 10 or 30 mg/kg
methyleugenol. Cytologic alteration such as changed
tinctorial staining qualities (eosinophilic or
basophilic) and increased mitotic activity, and Kupffer
cell pigmentation of yellow-gold to green pigment
within the cytoplasm of periportal hepatocytes, were
characteristic at 100 mg/kg doses and above.
Moreover, bile duct hyperplasia, consisting of
minimal to moderate proliferation of small bile
ductules within portal areas, was observed (11).
In a previous study by the present authors, we also
observed some degeneration in the liver, kidney, and
small intestine of rats at doses of 10 and 30 mg/kg/day
using a light microscope (18). We observed a
widening of the sinusoidal area, membrane loss and
fusion, cytoplasmic vacuolization in hepatocytes, and
degeneration of the endothelium and pyknotic nuclei
in the liver. In the present study, we observed
increased swelling of the sER and cytoplasmic
vacuolization in hepatocytes. These findings are
consistent with the light microscopic observations in
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previous research and may indicate that hepatocytes
attempt to metabolize methyleugenol.
We observed an accumulation of electron-dense
particles in the sER sacs in hepatocytes of the 10
mg/kg/day dose group. This accumulation may
indicate an attempt to metabolize the methyleugenol
before the ER induction by the hepatocytes. In our
previous study, there was a significant increase in the
total amount of protein in the liver, but not in the
kidney or small intestine for the 10 and 30 mg/kg/day
doses (18). This ER induction and increase in the total
amount of protein may be explained as an adaptive
response of hepatocytes against methyleugenol.
Invaginations in the nucleus membrane were
observed, and this is indicative of a disorder in
nucleus metabolism. This may be due to the extension
of degeneration of the endomembrane system.
Bile duct hyperplasia of the liver has been reported
using a light microscope for doses of 300 mg/kg and
above (11). We did not observe any hyperplasia of the
bile duct in the 10 and 30 mg/kg/day dose groups by
light microscope in our previous study, but, in the
present study, extensions in bile canaliculi and
increasing microvilli of canaliculi cells in the liver
were observed by electron microscope. Bilirubin
molecules could not be observed using routine
electron microscopy because of their low density (19).
However, extensions in the bile canaliculi and the
increase in the microvilli of canaliculi cells may be
associated with an excessive excretion of bile from the
hepatocytes to the bile canaliculi. Additionally, the
increase of mitochondria and the decrease of glycogen
may corroborate active bilirubin transport, which
needs energy. The increase in lysosomes, especially in
the 30 mg/kg/day dose group, may be another
ultrastructural sign of a response against
methyleugenol.
In conclusion, we may speculate that
methyleugenol causes liver damage at an
ultrastructural level based on our electron microscope
observations and the enzymatic evidence for the 10
and 30 mg/kg/day dose groups. Further study,
including ultrastructural evaluation, may provide
greater insight into the dose dependent toxicity of
methyleugenol.
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